| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages St... |
| 09 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
FIRST SUPPLEMENTAL INDENTURE, dated as of October 9, 2026, between Vaxcyte, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the Base Indenture (as... |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) |
| 03 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadershi... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 |
| 15 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026. Dr. Lukatch’s retirement was not the result of any disagreem... |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026. Mr. Lee’s retirement was not the result of any disagreement or d... |
| 16 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 15, 2026, Vaxcyte, Inc. (the “Company”) held its Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of a... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults |
| 24 Feb 2026 |
8-K: Other Events
Vaxcyte, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Leerink Partners LLC, as sales agent and/or principal (the “Agent”), shares o... |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission |
| 02 Feb 2026 |
8-K: Other Events
Vaxcyte, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Jefferies LLC (“Jefferies”), Leerink Partners LLC (“Leerink Partners”), and Evercore Group L.L.C. (“Evercore”) and each of... |
| 19 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This First Amendment to Executive Change in Control and Severance Agreement (the “Amendment”) is effective as of December 31, 2025, by and between [•] (the “Executive”) and Vaxcyte, Inc., a Delaware corporation (the “Company”). |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study |
| 30 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
On September 24, 2025 (the “Effective Date”), Vaxcyte, Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Patheon Manufacturing Services LLC (“Patheon”), part of Thermo Fisher Scientific. Under the Agree... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) |
| 17 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, Vaxcyte, Inc. (the “Company”) held its Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of a... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- |
| 01 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which... |
| 31 Mar 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 VAX-24 Infant Phase 2 Dose- Finding Study Topline Results March 31, 2025 |
Loading...